Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
RNA Interference01:23

RNA Interference

24.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioinspired Hydrogel Remodels the Niche after Spinal Cord Injury for Neural Reconnection by Promoting Angiogenesis and Reducing Inflammation.

Acta biomaterialia·2026
Same author

From local tissue repair to systemic precision orthopaedics: recent advances in musculoskeletal regeneration and translational medicine.

Journal of orthopaedic translation·2026
Same author

Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.

Discover oncology·2026
Same author

Notch signaling-targeted biomimetic hydrogel constructs an anti-inflammatory "flood-control" system to alleviate pyroptosis for intervertebral disc degeneration treatment.

Materials today. Bio·2026
Same author

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Future oncology (London, England)·2026
Same author

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Lancet (London, England)·2026

Related Experiment Video

Updated: May 4, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K

Polymeric systems as nanodevices for siRNA delivery.

Marcio J Tiera, Qin Shi, Hellen Franciane Gonçalves Barbosa

  • 1Department of Chemistry and Environmental Sciences, UNESP-São Paulo State University, São José do Rio Preto, Brazil. mit@ibilce.unesp.br.

Current Gene Therapy
|December 27, 2013
PubMed
Summary

Nanodevices using biodegradable polymers enhance small interfering RNA (siRNA) delivery for treating diseases. Strategies like cell-specific targeting improve siRNA efficiency and specificity.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.3K

Related Experiment Videos

Last Updated: May 4, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.3K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Nanomedicine

Background:

  • Small interfering RNAs (siRNAs) offer therapeutic potential for various diseases by silencing gene expression.
  • Gene silencing via siRNA faces challenges in efficient and specific delivery.
  • Nanodevices represent a promising platform for overcoming siRNA delivery hurdles.

Purpose of the Study:

  • To review advanced strategies for improving siRNA delivery using nanodevices.
  • To highlight the role of biodegradable synthetic polymers and polysaccharides in nanodevice assembly.
  • To discuss methods for enhancing siRNA efficiency and specificity through targeted delivery.

Main Methods:

  • Assembly of nanodevices with biodegradable synthetic polymers and polysaccharides.
  • Development of multilayer systems and stimuli-responsive polymers for controlled release.
  • Incorporation of ligands or antibodies for cell-specific targeting of nanodevices.

Main Results:

  • Nanodevices demonstrate significant progress in enhancing siRNA delivery.
  • Biodegradable materials and advanced synthetic routes contribute to high delivery efficiencies.
  • Cell-specific targeting strategies improve the specificity and efficacy of siRNA-based therapies.

Conclusions:

  • Nanodevice-based siRNA delivery is a rapidly advancing field with broad therapeutic implications.
  • The combination of novel materials and targeted delivery approaches holds great promise for future treatments.
  • Continued innovation in nanocarrier design is crucial for realizing the full potential of siRNA therapeutics.